About Abbott Laboratories
https://www.abbott.comAbbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices.
CEO
Robert B. Ford
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2013-01-02 | Forward | 5000:2399 |
| 2004-05-03 | Forward | 2500:2339 |
ETFs Holding This Stock
Summary
Showing Top 3 of 893
Ratings Snapshot
Rating : A-
Most Recent Analyst Grades
Grade Summary
Showing Top 6 of 16
Price Target
Institutional Ownership
METATRON CAPITAL SICAV PLC
Shares:1.77B
Value:$221.04B
VANGUARD GROUP INC
Shares:173.15M
Value:$21.64B
BLACKROCK, INC.
Shares:141.56M
Value:$17.69B
Summary
Showing Top 3 of 4,173
About Abbott Laboratories
https://www.abbott.comAbbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $11.37B ▲ | $4.31B ▲ | $1.64B ▼ | 14.46% ▼ | $0.94 ▼ | $3.02B ▼ |
| Q2-2025 | $11.14B ▲ | $4.24B ▲ | $1.78B ▲ | 15.97% ▲ | $1.02 ▲ | $3.05B ▲ |
| Q1-2025 | $10.36B ▼ | $3.76B ▲ | $1.32B ▼ | 12.79% ▼ | $0.76 ▼ | $2.67B ▼ |
| Q4-2024 | $10.97B ▲ | $3.61B | $9.23B ▲ | 84.1% ▲ | $5.33 ▲ | $2.99B ▲ |
| Q3-2024 | $10.63B | $3.61B | $1.65B | 15.48% | $0.95 | $2.91B |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $7.73B ▲ | $84.18B ▲ | $32.92B ▼ | $50.95B ▲ |
| Q2-2025 | $7.28B ▲ | $84B ▲ | $33.17B ▲ | $50.56B ▲ |
| Q1-2025 | $6.84B ▼ | $81.45B ▲ | $32.38B ▼ | $48.81B ▲ |
| Q4-2024 | $7.97B ▲ | $81.41B ▲ | $33.51B ▼ | $47.66B ▲ |
| Q3-2024 | $7.79B | $74.36B | $34.33B | $39.8B |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $1.64B ▼ | $2.79B ▲ | $-457M ▲ | $-1.76B ▼ | $560M ▲ | $2.29B ▲ |
| Q2-2025 | $1.78B ▲ | $2.05B ▲ | $-582M ▼ | $-1.1B ▲ | $419M ▲ | $1.54B ▲ |
| Q1-2025 | $1.32B ▼ | $1.42B ▼ | $-470M ▲ | $-2.06B ▼ | $-1.08B ▼ | $933M ▼ |
| Q4-2024 | $9.23B ▲ | $2.87B ▲ | $-866M ▼ | $-1.86B ▼ | $58M ▼ | $2.15B ▼ |
| Q3-2024 | $1.65B | $2.71B | $-594M | $-1.58B | $571M | $2.15B |
Revenue by Products
| Product | Q4-2024 | Q1-2025 | Q2-2025 | Q3-2025 |
|---|---|---|---|---|
 Diagnostic Products | $2.52Bn ▲ | $2.05Bn ▼ | $5.90Bn ▲ | $6.00Bn ▲ |
 Established Pharmaceutical Products | $1.27Bn ▲ | $1.26Bn ▼ | $1.38Bn ▲ | $1.51Bn ▲ |
 Medical Devices | $5.05Bn ▲ | $4.89Bn ▼ | $5.37Bn ▲ | $5.45Bn ▲ |
 Nutritional Products | $2.13Bn ▲ | $2.15Bn ▲ | $2.21Bn ▲ | $2.15Bn ▼ |
Revenue by Geography
| Region | Q4-2024 | Q2-2025 | Q1-2025 | Q3-2025 |
|---|---|---|---|---|
 NonUS | $6.63Bn ▲ | $6.87Bn ▲ | $6.19Bn ▼ | $7.07Bn ▲ |
 UNITED STATES | $4.34Bn ▲ | $4.28Bn ▼ | $4.17Bn ▼ | $4.30Bn ▲ |
CEO
Robert B. Ford
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2013-01-02 | Forward | 5000:2399 |
| 2004-05-03 | Forward | 2500:2339 |
ETFs Holding This Stock
Summary
Showing Top 3 of 893
Ratings Snapshot
Rating : A-
Most Recent Analyst Grades
Grade Summary
Showing Top 6 of 16
Price Target
Institutional Ownership
METATRON CAPITAL SICAV PLC
Shares:1.77B
Value:$221.04B
VANGUARD GROUP INC
Shares:173.15M
Value:$21.64B
BLACKROCK, INC.
Shares:141.56M
Value:$17.69B
Summary
Showing Top 3 of 4,173